George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Department of Dermatology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Cutis. 2020 Jun;105(6):E9-E12.
Anti-programmed cell death 1 (PD1) targeted immune checkpoint inhibitors such as nivolumab and pembrolizumab are increasingly used to treat advanced malignancies such as melanoma, non-small cell lung cancer, urothelial cancer, and renal cell carcinoma. A rare but increasingly reported adverse effect of anti-PD1 therapy is bullous pemphigoid (BP), an autoimmune blistering disease directed against BP antigen 1 and BP antigen 2 in the basement membrane of the epidermis. We present 3 cases of BP secondary to anti-PD1 immunotherapy in patients with melanoma and non-small cell lung cancer to highlight the diagnosis and treatment of this condition and emphasize the importance of the dermatologist in the care of patients with immunotherapy-related skin disease.
抗程序性细胞死亡蛋白 1（PD1）的免疫检查点抑制剂，如纳武利尤单抗和帕博利珠单抗，越来越多地被用于治疗黑色素瘤、非小细胞肺癌、尿路上皮癌和肾细胞癌等晚期恶性肿瘤。抗 PD1 治疗的一种罕见但越来越多报道的不良反应是大疱性类天疱疮（BP），这是一种针对表皮基底膜中 BP 抗原 1 和 BP 抗原 2 的自身免疫性水疱病。我们报告了 3 例黑色素瘤和非小细胞肺癌患者因抗 PD1 免疫治疗而发生的 BP，以强调这种情况的诊断和治疗，并强调皮肤科医生在免疫治疗相关皮肤病患者护理中的重要性。
